Effect of intermittent cyclical etidronate therapy on bone mass and fracture rate in women postmenopausal osteoporosis

Storm, T.; Thamsborg, Gorm; Steiniche, Torben; Genant, Harry K.; Oh, Sørensen

doi:10.1016/0378-5122(91)90293-y

Cited by 164 publications

(230 citation statements)

References 0 publications

Supporting

Mentioning

211

Contrasting

Unclassified

Order By: Relevance

“…(1)(2)(3)(4)(5)(6)(7)(8) Generally, these can be divided into two types: (1) antiresorptive treatments such as bisphosphonates (1,2,4,6,7) that bring about a prompt decrease in biochemical markers of bone resorption followed a few months later by a reduction in bone formation markers (9) and (2) anabolic agents (currently only parathyroid hormone) (5,10) that bring about a prompt increase in bone formation followed a few weeks later by an increase in bone resorption. (11) Many modern treatments for osteoporosis have a profound effect on bone remodeling, and studies of bone turnover have an important role in the evaluation of their effect on bone quality.…”

Section: Introductionmentioning

confidence: 99%

Differential effects of teriparatide on regional bone formation using 18F-fluoride positron emission tomography

Frost

Siddique

Blake

et al. 2010

Journal of Bone and Mineral Research

View full text Add to dashboard Cite

Teriparatide increases skeletal mass, bone turnover markers, and bone strength, but local effects on bone tissue may vary between skeletal sites. We used positron emission tomography (PET) to study 18 F-fluoride plasma clearance (K i ) at the spine and standardized uptake values (SUVs) at the spine, pelvis, total hip, and femoral shaft in 18 postmenopausal women with osteoporosis. Subjects underwent a 1-hour dynamic scan of the lumbar spine and a 10-minute static scan of the pelvis and femurs at baseline and after 6 months of treatment with 20 mg/day teriparatide. Blood samples were taken to derive the arterial input function and lumbar spine K i values evaluated using a three-compartment model. SUVs were calculated for the spine, pelvis, total hip, and femoral shaft. After 6 months treatment with teriparatide, spine K i values increased by 24% (p ¼ .0003), while other model parameters were unchanged except for the fraction of tracer going to bone mineral (k 3 /[k 2 þ k 3 ]), which increased by 23% (p ¼ .0006). In contrast to K i , spine SUVs increased by only 3% (p ¼ .84). The discrepancy between changes in K i and SUVs was explained by a 20% decrease in 18 F À plasma concentration. SUVs increased by 37% at the femoral shaft (p ¼ .0019), 20% at the total hip (p ¼ .032), and 11% at the pelvis (p ¼ .070). Changes in bone turnover markers and BMD were consistent with previous trials. We conclude that the changes in bone formation rate during teriparatide treatment as measured by 18 F À PET differ at different skeletal sites, with larger increases in cortical bone than at trabecular sites. ß

show abstract

Section: Introductionmentioning

confidence: 99%

Differential effects of teriparatide on regional bone formation using 18F-fluoride positron emission tomography

Frost

Siddique

Blake

et al. 2010

Journal of Bone and Mineral Research

View full text Add to dashboard Cite

show abstract

“…Compared with tamoxifen, toremifene is more oestrogen antagonistic than agonistic in rat (Di Salle et al, 1990). At present, no data are available on the effect of toremifene on bone.Since bisphosphonates prevent post-menopausal bone loss (Chesnut 1984; Reginster et al, 1989;Storm et al, 1990;Watts et al, 1990;Giannini et al, 1993;Harris et al, 1993;Reid et al, 1994;Filipponi et al, 1995;Liberman et al, 1995) and in advanced breast cancer reduced the development of new bone metastases (Elomaa et al, 1983;Martoni et al, 1991;Paterson et al, 1993;Van Holten Verzantvoort et al, 1993), they are attractive candidates for the treatment of patients with early breast cancer. We performed a prospective, open, randomized study to determine the effect of oral clodronate in post-menopausal women with primary breast cancer treated with adjuvant antioestrogens, Received 24 July 1996 Revised 10 October 1996 Accepted 15 October 1996 Correspondence to: Elomaa, Department of Oncology, Helsinki University Central Hospital, Haartmaninkatu 4, FIN-00290 Helsinki, Finland tamoxifen or toremifene.…”

mentioning

confidence: 99%

Clodronate improves bone mineral density in post-menopausal breast cancer patients treated with adjuvant antioestrogens

Saarto

Blomqvist²,

Välimäki³

et al. 1997

Br J Cancer

115

View full text Add to dashboard Cite

Summary The effect of clodronate on bone mineral density (BMD) was studied in 121 post-menopausal breast cancer women without skeletal metastases. In addition, two antioestrogens, tamoxifen and toremifene, were compared in their action on bone mineral density. Patients were randomized to have an adjuvant antioestrogen treatment either 20 mg of tamoxifen or 60 mg of toremifene daily for 3 years. In addition all patients were randomized to have 1600 mg of oral clodronate daily or to act as control subjects. BMD of the lumbar spine and femoral neck were measured by dual-energy radiographic absorptiometry before therapy and at 1 and 2 years. At 2 years, clodronate with antioestrogens markedly increased BMD in the lumbar spine and femoral neck by 2.9% and 3.7% (P = 0.001 and 0.006 respectively). There were no significant changes in BMD in the patients given antioestrogens only. No significant differences were found between tamoxifen and toremifene on bone mineral density. Clodronate with antioestrogens significantly increased bone mass in the lumbar spine and femoral neck. Both antioestrogens, tamoxifen and toremifene, similarly prevented bone loss in the lumbar spine and femoral neck.Keywords: antioestrogens; bone mineral density; bisphosphonate; breast neoplasm; post-menopausal osteoporosis; toremifene Adjuvant antioestrogen treatment with tamoxifen significantly improves the survival of post-menopausal women with primary breast cancer (EBCTCG, 1992). Tamoxifen has oestrogen agonistic effects on bone and therefore prevents bone loss in postmenopausal women (Love et al, 1992;Ward et al, 1993;Kristensen et al, 1994;Powles et al, 1996). Tamoxifen has been shown to prevent bone loss predominantly in the lumbar spine (Love et al, 1992;Kristensen et al, 1994), but in two randomized studies this was also true for the upper femur (Ward et al, 1993;Powles et al, 1996).Toremifene is a close analogue to tamoxifen with demonstrated efficacy in advanced breast cancer (Valavaara et al, 1988). Compared with tamoxifen, toremifene is more oestrogen antagonistic than agonistic in rat (Di Salle et al, 1990). At present, no data are available on the effect of toremifene on bone.Since bisphosphonates prevent post-menopausal bone loss (Chesnut 1984; Reginster et al, 1989;Storm et al, 1990;Watts et al, 1990;Giannini et al, 1993;Harris et al, 1993;Reid et al, 1994;Filipponi et al, 1995;Liberman et al, 1995) and in advanced breast cancer reduced the development of new bone metastases (Elomaa et al, 1983;Martoni et al, 1991;Paterson et al, 1993;Van Holten Verzantvoort et al, 1993), they are attractive candidates for the treatment of patients with early breast cancer. We performed a prospective, open, randomized study to determine the effect of oral clodronate in post-menopausal women with primary breast cancer treated with adjuvant antioestrogens, Received 24 July 1996 Revised 10 October 1996 Accepted 15 October 1996 Correspondence to: Elomaa, Department of Oncology, Helsinki University Central Hospital, Haartmaninkatu 4, FIN-00290 Hels...

show abstract

“…It substantially reduced the long-term risk of vertebral and nonvertebral fractures (Black et al, 1996;Liberman & Weiss, 1995). Therefore, we considered that this agent would be useful for the treatment of bone loss in AN patients because only 2 weeks of administration is reported to prevent bone absorption for 3 months in women with PMO (Storm, Thamsborg, Steiniche, Genant, & Sorensen, 1990). We hypothesized that etidronate may be effective in increasing bone formation and preventing bone resorption and fractures in AN.…”

Section: Resultsmentioning

confidence: 99%

The effects of bone therapy on tibial bone loss in young women with anorexia nervosa

Nakahara

Nagai

Tanaka

et al. 2006

Int. J. Eat. Disord.

View full text Add to dashboard Cite

Effect of intermittent cyclical etidronate therapy on bone mass and fracture rate in women postmenopausal osteoporosis

Cited by 164 publications

References 0 publications

Differential effects of teriparatide on regional bone formation using 18F-fluoride positron emission tomography

Differential effects of teriparatide on regional bone formation using 18F-fluoride positron emission tomography

Clodronate improves bone mineral density in post-menopausal breast cancer patients treated with adjuvant antioestrogens

The effects of bone therapy on tibial bone loss in young women with anorexia nervosa

Contact Info

Product

Resources

About